Prognostic value of membrane sodium-iodide symporter expression in metastatic papillary thyroid cancer for radioiodine refractoriness risk assessment
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction. The development of radioiodine resistance in papillary thyroid carcinoma remains the primary cause of radioiodine therapy failure and disease recurrence. The implementation of preoperatively quantified functional activity of the membrane sodium-iodide symporter (NIS), combined with molecular genetic profiling, opens new avenues for precise surgical extent selection. Aim. To evaluate the degree of dedifferentiation in lymph node metastases of papillary thyroid carcinoma and to assess the feasibility of predicting radioiodine resistance based on preoperative BRAF status determination and quantitative membrane NIS expression levels. Materials and methods. A prospective observational study was conducted, including 129 patients with papillary thyroid carcinoma. All participants underwent preoperative fine-needle aspiration biopsy (FNAB) of the primary tumor, and 28 patients also underwent FNAB of metastatic lymph nodes. Membrane NIS expression levels in needle washouts during FNAB were quantified using flow cytometry, and the presence of the BRAF V600E mutation was determined by real-time polymerase chain reaction. The follow-up period was 60 months. Results. Structural recurrence over a 5-year follow-up period was identified in 49 (38 %) patients. The mean level of membrane NIS expression in the primary tumor was statistically significantly lower in patients with recurrence compared to those without recurrence: 2.0 % vs 4.7 % (p 0,001). No statistically significant differences in NIS levels were found based solely on the BRAF status of the primary tumor (p = 0.535) or lymph nodes (p = 0.872). However, in the BRAFV600E-positive tumor group, a strong positive correlation was observed between primary tumor NIS expression and its level in metastases (Rs = 0.824; p 0.001). A linear regression model was developed: NISlymph node = –0.813 + 0.733 × NIStumor (95 % confidence interval for B coefficient: 0.441–1.026; Rs = 0.824; p 0.001), enabling preoperative prediction of the functional status of metastases. Conclusion. Decreased membrane NIS expression is not only a predictor of radioiodine refractoriness but also a key marker of papillary thyroid carcinoma dedifferentiation. The concurrent presence of the BRAFV600E mutation and a primary tumor NIS ≤ 2 % may warrant consideration for extending the surgical scope to include prophylactic central neck dissection (level VI). This ensures surgical elimination of radioiodine resistant metastatic foci that would otherwise fail to respond to subsequent radioiodine therapy.
Source: Head and neck tumors (HNT)
Institution: Ministry of Health of the Russian Federation
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7236853928
